Structure Therapeutics (NASDAQ:GPCR) Trading Down 3.4%

Structure Therapeutics Inc. (NASDAQ:GPCR) was down 3.4% during trading on Wednesday . The company traded as low as $40.66 and last traded at $40.72. Approximately 61,403 shares changed hands during trading, a decline of 90% from the average daily volume of 605,746 shares. The stock had previously closed at $42.17.

Analysts Set New Price Targets

Separately, Lifesci Capital reissued an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $89.17.

Structure Therapeutics Trading Down 0.1 %

The firm has a 50-day simple moving average of $41.86 and a 200-day simple moving average of $48.08.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC purchased a new stake in shares of Structure Therapeutics in the fourth quarter worth about $28,000. Tower Research Capital LLC TRC lifted its stake in Structure Therapeutics by 1,274.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 921 shares of the company’s stock worth $46,000 after purchasing an additional 854 shares in the last quarter. Barclays PLC bought a new position in Structure Therapeutics in the 2nd quarter valued at $47,000. Picton Mahoney Asset Management purchased a new position in shares of Structure Therapeutics during the 3rd quarter valued at $116,000. Finally, Sectoral Asset Management Inc. bought a new position in shares of Structure Therapeutics in the fourth quarter worth $139,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.